source
- Synthetic lethality hype may spark new wave of biotech mergersThe piece highlights rising enthusiasm for synthetic lethality as a cancer‑treatment strategy, especially after recent data releases. In an early‑stage trial, Tango Therapeutics reported that pati…
- Takeda’s oral psoriasis drug outperforms Bristol Myers’ Sotyktu in Phase 3 trialTakeda announced that its experimental oral medication for plaque psoriasis achieved superior results compared with Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. The trial measur…